Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Clinical trials

Topic: Brain proteins, microglia and lab models

Plain-language summary

Intervention HMTM 16 mg/day and 8 mg/day were compared with methylthioninium chloride (MTC) 4 mg twice weekly, intended as an inactive urinary colourant to preserve blinding with respect to possible urinary discolouration caused by HMTM. Results It was not possible to demonstrate significant differences on the co-primary clinical endpoints (ADAS-cog 11 and ADCS-ADL 23 ) at 52 weeks due to symptomatic activity in the control arm. In participants with MCI, statistically significant differences in cognitive decline (ADAS-cog 13 ) emerged at 78 weeks (p = 0·0291) and 104 weeks (p = 0·0308) between early- and delayed-start HMTM 16 mg/day in analyses specified prior to the 24-month database lock. Statistically significant cognitive improvement over baseline score was sustained for 78 weeks in the early start MCI group, with no significant cognitive or functional decline to 104 weeks. There was a significant reduction in progression of neurodegeneration measured by NfL change (p = 0·0291) at 52 weeks in the whole population, consistent with significant reductions in progression of grey matter atrophy at 52 and 104 weeks, and a reduction in progression of tau pathology (pTau217, p = 0·0165) in MCI. In participants with MCI, significant clinical separation was seen only at 78 and 104 weeks.

What this study adds

Evidence grade: Null result

The record lists 598 participants. This Phase 3 trial could not show significant differences on its main clinical endpoints at 52 weeks because the control arm also showed symptomatic activity. Its stated limit: Failed primary endpoints; comparator was a low dose of the same compound rather than true placebo; positive results are subgroup and secondary analyses; sponsored and authored by the developer.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Wischik, C. M., Stefanacci, R., Bentham, P., Gauthier, S., Zetterberg, H., Wilcock, G. K., et al. (2026). Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's disease. The Journal of Prevention of Alzheimer's Disease. https://doi.org/10.1016/j.tjpad.2026.100480

Vancouver

Wischik CM, Stefanacci R, Bentham P, Gauthier S, Zetterberg H, Wilcock GK, et al. Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's disease. The Journal of Prevention of Alzheimer's Disease. 2026. doi:10.1016/j.tjpad.2026.100480. PMID: 41570392.

BibTeX

@article{wischik2026-41570392,
  author  = {Wischik, C. M. and Stefanacci, R. and Bentham, P. and Gauthier, S. and Zetterberg, H. and Wilcock, G. K. and Froelich, L. and Burns, A. and MacSweeney, E. and Ballard, C. and others},
  title   = {{Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's disease}},
  journal = {The Journal of Prevention of Alzheimer's Disease},
  year    = {2026},
  doi     = {10.1016/j.tjpad.2026.100480},
  pmid    = {41570392},
  url     = {https://doi.org/10.1016/j.tjpad.2026.100480}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This Phase 3 trial could not show significant differences on its main clinical endpoints at 52 weeks because the control arm also showed symptomatic activity. In participants with mild cognitive impairment, some cognitive differences emerged at 78 and 104 weeks, and there were reductions in markers of neurodegeneration and tau pathology.

Study details

Limitations

Failed primary endpoints; comparator was a low dose of the same compound rather than true placebo; positive results are subgroup and secondary analyses; sponsored and authored by the developer.

How this study scored 60/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 11 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 2 of 5; Impact for its field and year 5 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 1 of 4; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read left out, no data. 59 of the 98 points it could be judged on, which is 60 of 100. Total 60 of 100.59 of the 98 points we could judge = 60 of 100

Published in a peer-reviewed journal, and it is a large phase 3 trial. Scored zero for effect reported and randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 59 of the 98 points we could judge it on, which is 60 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (The Journal of Prevention of Alzheimer's Disease)
Journal's citation record 0 / 4 The Journal of Prevention of Alzheimer s Disease: journal h-index 63 (OpenAlex, 2026-10-29)
Study design 11 / 12 A large phase 3 trial
Strength of evidence 3 / 5 Rated “null-result” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 2 / 4 598 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 9 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 4.5 citations a year over 2 year(s) since 2026
Impact for its field and year 5 / 6 Cited 37.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 9 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Bjoern O. Schelter: h-index 15 (OpenAlex, whole career)
Institution's track record 2 / 3 University of Oxford: institution h-index 2,205 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 21 institution(s) in 6 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41570392)
Free to read — / 2 Access not recorded — left out of this score
Points 59 / 98 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 59 of the 98 points we could judge it on is 60 out of 100.
Total 60 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.

Related studies in Clinical trials from nearby years

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Clinical trials

See all studies in Clinical trials →